TEL AVIV Nov 15 Teva Pharmaceutical Industries reported better than expected third-quarter profit as sales were boosted by its $40.5 billion acquisition of Allergan's generic drug business on August 2.
Hedge funds have recently made changes to their positions in the stock.
Boasting a price of $41.03, Teva Pharmaceutical (NYSE:TEVA) traded -1.33% lower on the day.
Average EPS forecast for the current year is $5.18 according to 26 analysts making projections for Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA). The stock appeared -37.16% below its 52-week highs and is up 1.91% for the last five trades.
Over the last twelve months Teva Pharmaceutical's stock price has increased from 0.00 to 41.08, a change of 0%. Now shares have been suggested as BUY from 2 brokerage firms and recommended as Strong Buy by 9 brokerage firms.0 brokerage firms have issued Sell rating for the company and Strong Sell rating was issued by 0 brokerage firms.7 brokerage firms have rated the company as a Hold. We have $36.15 PT which if reached, will make NYSE:TEVA worth $1.95B less. The stock has a 50 day moving average price of $43.93 and a 200-day moving average price of $50.26.
Whereas Teva took on water despite a compelling outlook, Finnish telecom technology company Nokia was hit hard on Tuesday because of a lackluster fourth quarter outlook. Following Earnings result, share price were DOWN 12 times out of last 18 Qtrs. The company net profit margin is -78.50% and gross profit margin is 63.90%.
Mizuho analyst Irina Koffler attributed the revenue miss to its speciality drugs business, which had revenue of $2.05 billion versus $2.06 billion forecast by analysts. EPS or Earning per Share stands at $1.5.
Analysts expect, on average, a top line of $6.48 billion. Teva Pharmaceutical Industries's dividend payout ratio (DPR) is presently 77.85%. Volume of about 11 million was more than 30 times the daily average of around 350,000 shares.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) reported its previous quarter on 08/04/2016 where it reported the Actual Earnings of $1.25. Krilogy Financial LLC increased its stake in Teva Pharmaceutical Industries by 1.0% in the second quarter. Iowa State Bank raised its position in Teva Pharmaceutical Industries by 3.3% in the second quarter. They issued an "equal weight" rating and a $46.00 price objective for the company. The Average Volume for the stock is measured as 8.34 Million. Trust Co now owns 13,980 shares of the company's stock worth $748,000 after buying an additional 40 shares during the period.
Teva Pharmaceutical Industries Ltd (ADR) is a global pharmaceutical company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Revenue in its generic medicine segment grew 32% to $2.9 billion, largely due to the Allergan deal.
Global sales of its best-selling multiple sclerosis drugCopaxone slipped 2 percent to $1.1 billion.